- Medical - Devices
- Healthcare
-
-46.68
EPS
-
-6.97
P/E
-
9.08B
MARKET CAP
-
0.00%
DIV YIELD
Company Overview
1000 ALFRED NOBEL DRIVE,HERCULES CA 94547,5107247000
CEO
Mr. Norman D. Schwartz
Employess
8000
Sector
Healthcare
Industry
Medical - Devices
Website
https://www.bio-rad.com
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Next Earnings Date
Oct. 24, 2024
Ex Dividends date
--
Dividend Date
--
YTD Performance
-0.82%
Fiscal Year End
12-31
IPO Date
1980-02-27
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 2.28% | 3.13% | 1.62% | -4.67% |
EPS | -24.60% | -22.89% | -5.39% | 82.08% |
Equity | 14.86% | 16.83% | -4.00% | -9.09% |
Cash | 2.00% | -1.31% | -15.19% | -6.97% |
Return On Capital (ROIC) | 2.70% | 3.05% | 3.04% | 2.89% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 41.4 | 0.465 | 0.489 | 1.8 | 426 |
Long Term Debt | 1,190 | 1,200 | 10.5 | 12.3 | 13.6 |
LT Finance Leases | 175 | 190 | 223 | 223 | 223 |
Shares Outstanding | 29.2 | 29.8 | 29.8 | 29.8 | 29.8 |
Market Cap | 9,430 | 12,500 | 22,500 | 17,400 | 11,000 |
Price
News
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
1 monthMINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million.
prnewswire.comBIO-TECHNE DECLARES DIVIDEND
1 monthMINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024.
prnewswire.comBio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
2 monthsBio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
zacks.comBio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
2 monthsBio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President and CEO Andy Last - Executive Vice President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and CFO Conference Call Participants Patrick Donnelly - Citi Daniel Leonard - UBS Tycho Peterson - Jefferies Jack Meehan - Nephron Research Operator Good day, everyone, and welcome to today's Bio-Rad Second Quarter 2024 Earnings Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
seekingalpha.comBio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
2 monthsBio-Rad Laboratories (BIO) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $3 per share a year ago.
zacks.comBio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products
2 monthsBio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
reuters.comBio-Rad Reports Second-Quarter 2024 Financial Results
2 monthsHERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sales decreased 5.4 percent compared to the same period in 2023. Life.
businesswire.comWhat's in Store for These 4 MedTech Stocks in Q2 Earnings?
2 monthsHere is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
zacks.comBIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM
2 monthsMINNEAPOLIS , July 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce the launch of the Leo™ System. This next-generation Simple Western™ instrument offers higher throughput, flexibility, and efficiency over the current Jess™ and Abby™ Simple Western Systems.
prnewswire.comAll You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
2 monthsBio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.comBIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO
2 monthsMINNEAPOLIS , July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity.
prnewswire.comBio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
2 monthsHERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-343-4849 within the U.S. or 203-518-9856 outside the U.S., acce.
businesswire.com